CTLA4 and skin basal cell carcinoma: Interestingly, another case-control study demonstrated that the CTLA-4 levels in patients with basal cell carcinoma (BCC) were significantly increased compared with the healthy individuals, with the AUC of 0.757 (95% CI: 0.597–0.859) for the BCC prediction model [38].